<DOC>
	<DOC>NCT01666249</DOC>
	<brief_summary>The anti-Rh immunoglobulin is an immunobiological containing high concentration of specific antibodies against factor D and "neutralizes" D antigen present in the Rh-positive fetal red blood cells (Rh +), which passed into the bloodstream of Rh-negative pregnant women (Rh). This a immunization study for clinical assessment of anti-Rh immunoglobulin (KamRho-DÂ®) in Rh and Coombs negative women with risk sensitization.</brief_summary>
	<brief_title>Clinical Efficacy of Postpartum Immunization of Rh and Coombs Negative Women With Sensitization Risk.</brief_title>
	<detailed_description>This a immunization, non-randomized phase III study in which women participants with RH and Coombs negative receive only one dose of 1500 IU anti-Rh immunoglobulin intramuscularly and will be following during six months to verification of negative Coombs maintenance. Safety evaluation data will include report of all adverse events (including type, frequency, intensity, seriousness, severity and action taken related to the investigational product).</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Fetomaternal Transfusion</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Agree to participate, sign and date the Informed Consent; 18 years old or older; Mothers who are Rhnegative, negative indirect Coombs analyzed by gel agglutination method, whose just deliveries Rh positive baby. Be participating simultaneously or have participated in another clinical trial within the last 12 months; Mothers who are allergic to any components of the formula; Mothers who have a history of IgA deficiency or IgA antibody present; Mothers who have a history of autoimmune hemolytic anemia with hemolysis or with preexisting risk of hemolysis; Mothers who have indirect Coombs test positive in the beginning of the treatment; Rhnegative mothers whose delivered Rhnegative babies; Abnormalities of the coagulation system; Patients who made use of vaccines made with live pathogens in the last 03 months or will make during the study; Patients with clinical diagnosis of prenatal liver and / or severe nephropathy; Principal Investigator of the study criteria;</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>FMH; anti-Rh; efficacy</keyword>
</DOC>